10 Forest Laboratories Analyst Ratings, Earnings, Dividends and Insider Trades | $FRX | NYSE:FRX | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Forest Laboratories Company Profile (NYSE:FRX) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Forest Laboratories (NYSE:FRX) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 13 Hold Rating(s), 11 Buy Rating(s)Consensus Rating:Hold (Score: 2.46)Consensus Price Target: $68.59 27.56% downside) Analysts' Ratings History for Forest Laboratories (NYSE:FRX) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/24/2014Credit SuisseDowngradeOutperform -> Neutral$85.00 -> $96.00View 2/20/2014SunTrustDowngradeBuy -> NeutralView 2/19/2014BarclaysBoost Price TargetEqual Weight$74.00 -> $90.00View 2/19/2014CRT CapitalDowngradeBuy -> Fair Value$78.00 -> $93.00View 2/19/2014Buckingham ResearchDowngradeBuy -> NeutralView 2/19/2014Goldman SachsDowngradeBuy -> Neutral$80.00 -> $85.00View 2/19/2014MizuhoDowngradeBuy -> Neutral$93.00View 2/18/2014Cantor FitzgeraldDowngradeBuy -> HoldView 2/18/2014Morgan StanleyUpgradeEqual Weight -> Overweight$86.00View 2/10/2014ZacksReiterated RatingOutperform -> Outperform$83.00View 2/4/2014JPMorgan Chase & Co.UpgradeNeutral -> Overweight$78.00View 1/23/2014ZacksReiterated RatingOutperform -> Outperform$80.00View 1/17/2014Credit SuisseUpgradeNeutral -> Outperform$60.00 -> $85.00View 1/14/2014ArgusBoost Price TargetBuy$62.00 -> $77.00View 1/9/2014UBS AGBoost Price TargetNeutral$57.00 -> $72.00View 1/9/2014CRT CapitalBoost Price TargetBuy$63.00 -> $78.00View 1/9/2014Buckingham ResearchUpgradeNeutral -> BuyView 1/9/2014MizuhoBoost Price TargetBuy$70.00 -> $90.00View 12/19/2013Piper JaffrayUpgradeNeutral -> OverweightView 12/11/2013ArgusReiterated RatingBuy$62.00View 12/11/2013UBS AGBoost Price TargetMarket Perform -> Neutral$49.00 -> $93.00View 12/6/2013ZacksUpgradeNeutral -> Outperform$67.00View 12/3/2013Goldman SachsBoost Price Target$65.00View 12/3/2013BarclaysBoost Price TargetEqual Weight$39.00 -> $50.00View 12/3/2013UBS AGBoost Price TargetNeutral$47.00 -> $57.00View 12/3/2013SunTrustUpgradeNeutral -> Buy$50.00 -> $72.00View 12/3/2013FBR Capital MarketsBoost Price TargetOutperform -> Outperform$59.00 -> $70.00View 11/26/2013Piper JaffrayUpgradeUnderweight -> Neutral$33.00 -> $49.00View 11/22/2013MizuhoBoost Price TargetBuy$50.00 -> $59.00View 10/30/2013FBR Capital MarketsInitiated CoverageMarket Perform$48.00View 10/25/2013BMO Capital MarketsUpgradeUnderperform -> Market Perform$27.00 -> $33.00View 10/23/2013BarclaysBoost Price TargetEqual Weight$36.00 -> $39.00View 10/23/2013ZacksReiterated RatingNeutral -> Neutral$49.00View 10/8/2013Credit SuisseInitiated CoverageNeutralView 9/18/2013GARP ResearchInitiated CoverageBuyView 7/24/2013ZacksReiterated RatingNeutral -> Neutral$46.00View 7/24/2013SusquehannaUpgradeNegative -> NeutralView 7/9/2013MizuhoBoost Price TargetBuy$44.00 -> $49.00View 7/8/2013Goldman SachsUpgradeNeutral -> BuyView 6/21/2013Goldman SachsUpgradeNeutral -> Buy$40.00 -> $50.00View 6/13/2013Cantor FitzgeraldBoost Price TargetBuy$45.00 -> $48.00View 6/12/2013Jefferies GroupReiterated RatingBuy$43.00 -> $48.00View 6/5/2013ArgusUpgradeHold -> Buy$46.00View 5/29/2013SunTrustInitiated CoverageNeutralView 5/29/2013TheStreetUpgradeHold -> BuyView 5/24/2013Janney Montgomery ScottReiterated RatingBuy$45.00View 5/23/2013BarclaysReiterated RatingEqual Weight$33.00View 5/9/2013BMO Capital MarketsInitiated CoverageUnderperform -> Underperform$27.00View 5/7/2013ZacksReiterated RatingNeutral -> Neutral$39.00View 5/2/2013BarclaysReiterated RatingEqual Weight$33.00View 4/24/2013ZacksReiterated RatingNeutral -> Neutral$39.00View 4/24/2013Deutsche BankReiterated RatingHold$36.00View 4/19/2013Leerink SwannBoost Price TargetOutperform$40.00 -> $42.00View 4/18/2013Cantor FitzgeraldLower Price TargetBuy$45.00View 4/17/2013Cantor FitzgeraldReiterated RatingBuy$48.00 -> $48.00View 4/2/2013SusquehannaInitiated CoverageNeutralView 3/27/2013CRT CapitalReiterated RatingBuy$44.00View 3/15/2013Credit SuisseBoost Price Target$44.00View 3/14/2013Sanford C. BernsteinReiterated RatingMarket Perform$39.00View 2/15/2013Jefferies GroupReiterated RatingBuy$43.00View 1/31/2013ZacksReiterated RatingNeutral -> Neutral$38.00View 1/31/2013Janney Montgomery ScottInitiated CoverageBuy$45.00View 1/30/2013Bank of AmericaReiterated RatingBuy$43.00 -> $45.00View 1/16/2013ZacksReiterated RatingNeutral -> Neutral$40.00View 1/16/2013Deutsche BankReiterated RatingHold$34.00 -> $36.00View 1/16/2013SusquehannaReiterated RatingNegative$29.00View 1/14/2013Cowen and CompanyReiterated RatingOutperformView 1/11/2013Leerink SwannReiterated RatingOutperformView 1/11/2013Goldman SachsUpgradeSell -> Neutral$33.00 -> $40.00View 12/20/2012Citigroup Inc.Boost Price TargetBuy$40.00 -> $44.00View 12/13/2012CRT CapitalReiterated RatingBuy$41.00View 12/10/2012Cowen and CompanyUpgradeNeutral -> OutperformView 12/7/2012MizuhoReiterated RatingBuy$45.00View 11/29/2012Citigroup Inc.Initiated CoverageBuyView 11/29/2012Cantor FitzgeraldReiterated Ratingbuy$48.00View 11/9/2012MizuhoInitiated CoverageBuy$45.00View 10/25/2012ZacksReiterated RatingNeutral -> Neutral$36.00View 10/23/2012Morgan StanleyCut EstimatesEqual Weight$35.00View 10/23/2012Needham & CompanyReiterated RatingHoldView 10/23/2012Needham & CompanyReiterated RatingHoldView 10/22/2012BarclaysReiterated RatingEqualweight$33.00View 10/17/2012ZacksReiterated RatingNeutral -> Neutral$37.00View 10/16/2012Cowen and CompanyDowngradeOutperform -> NeutralView 10/12/2012Cantor FitzgeraldReiterated RatingBuy$47.00View 10/5/2012Jefferies GroupReiterated RatingBuy$41.00View 10/2/2012ZacksReiterated RatingNeutral -> Neutral$38.00View 9/11/2012JPMorgan Chase & Co.Reiterated RatingNeutral$37.00View 8/31/2012Needham & CompanyReiterated RatingHoldView 8/31/2012Jefferies GroupReiterated RatingBuyView 8/9/2012JPMorgan Chase & Co.DowngradeOverweight -> Neutral$37.00View 7/26/2012ZacksReiterated RatingNeutral -> Neutral$35.00View 7/24/2012UBS AGReiterated RatingNeutralView 7/18/2012ZacksReiterated RatingNeutral -> Neutral$38.00View 7/18/2012Needham & CompanyReiterated RatingHoldView 7/17/2012Robert W. BairdReiterated RatingNeutralView 7/13/2012BarclaysReiterated RatingEqualweightView 6/21/2012Cantor FitzgeraldReiterated RatingBuyView 6/21/2012Goldman SachsReiterated RatingSellView 6/21/2012Piper JaffrayLower Price Target$27.00View 6/19/2012BarclaysReiterated RatingEqualweightView 6/13/2012ZacksReiterated RatingNeutral -> Neutral$36.00View 6/13/2012Morgan StanleyCut Estimates$35.00View 5/31/2012Leerink SwannUpgradeMarket Perform -> OutperformView 5/1/2012ThinkEquityBoost Price TargetBuy$40.00View 4/30/2012ZacksReiterated RatingNeutral -> Neutral$37.00View 4/26/2012AurigaInitiated CoverageHold$36.00View 4/18/2012ZacksReiterated RatingNeutral -> Neutral$37.00View 4/18/2012Needham & CompanyReiterated RatingHoldView 4/18/2012Cantor FitzgeraldBoost Price TargetBuy$41.00 -> $45.00View 4/13/2012Goldman SachsBoost Price TargetSell$30.00 -> $31.00View 4/11/2012Credit SuisseCut EstimatesOutperform$44.00View 3/28/2012ZacksReiterated RatingNeutral -> Neutral$36.00View (Data available from 3/10/2012 forward) Earnings History for Forest Laboratories (NYSE:FRX)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare1/21/2014Q314$0.05$0.07$827.25 million$846.80 millionViewN/AView 10/22/2013Q214$0.14$0.26$840.96 million$811.40 millionViewN/AView 7/23/2013Q1 2014$0.09$0.28$798.41 million$796.90 millionViewN/AView 4/23/2013Q4 2013$0.16$0.17$807.00 million$783.20 millionViewN/AView 1/15/2013Q3 2013($0.14)($0.21)$765.94 million$678.00 millionViewN/AView 10/16/2012$0.02$0.08ViewN/AView 7/17/2012$0.24$0.28ViewN/AView 4/17/2012$0.70$0.78ViewN/AView 1/17/2012$1.01$1.04ViewN/AView 10/18/2011$0.99$0.91ViewN/AView 7/19/2011$0.97$1.04ViewN/AView 4/19/2011$1.07$1.12ViewN/AView 1/18/2011$0.99$1.34ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Forest Laboratories (NYSE:FRX)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Forest Laboratories (NYSE:FRX)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare1/27/2014Howard SolomonDirectorSell250,000$65.41$16,352,500.00View 1/23/2014Howard SolomonDirectorSell250,000$67.13$16,782,500.00View 1/22/2014Jerome LynchSVPSell135,625$67.28$9,124,850.00View 8/26/2013Lawrence OlanoffDirectorSell1,104$42.96$47,427.84View 8/21/2013Perier Francis, Jr.CFOSell12,000$43.00$516,000.00View 9/4/2012Carl C IcahnMajor ShareholderBuy86,848$34.64$3,008,414.72View 8/29/2012Carl C IcahnMajor ShareholderBuy331,406$34.65$11,483,217.90View 8/24/2012Carl C IcahnMajor ShareholderBuy1,343,837$34.57$46,456,445.09View 8/21/2012Carl C IcahnMajor ShareholderBuy1,962,011$34.18$67,061,535.98View (Data available from 1/1/2013 forward) About Forest Laboratories Forest Laboratories, Inc. (Forest) develops, manufactures and sells branded forms of ethical drug products, which requires a physician's prescription. The Company's products include Namenda, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; Bystolic, a beta-blocker for the treatment of hypertension; Linzess, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; Tudorza, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and Viibryd, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder. In February 2014, it acquired Aptalis. In February 2014, Mayne Pharma Group Ltd completed the acquisition of the ESGIC, ESGIC PLUS, LORCET and LORCET PLUS brands and related assets from Forest Laboratories, Inc. Headlines: (3/4) Forest Laboratories and Adamas Pharmaceuticals Announce Forest’s Submission of New Drug Application for Memantine ... (2/27) Forest Laboratories Submits a New Drug Application for Nebivolol and Valsartan Combination in Hypertension (2/19) FOREST LABORATORIES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout (2/24) Forest Laboratories, Inc. Launches STRIDE Patient Support Program for COPD Franchise Products Tudorza® Pressair® and ... (2/18) Actavis to Acquire Forest Laboratories, Inc. for ~$25 Billion in an Equity and Cash Transaction (2/14) Forest Laboratories to Discontinue NAMENDA® Tablets, Focus on Once-Daily NAMENDA XR® (2/18) Actavis to Buy Forest Laboratories for $25 Billion (3/4) Forest Labs Seeks Bystolic-Diovan Approval Industry, Sector and Symbol: Sector: Healthcare Industry: Pharmaceuticals Sub-Industry: Pharmaceuticals Exchange: NYSE Symbol: FRX CUSIP: 34583810 Key Metrics: Previous Close: $95.1850 Day Moving Average: $79.5806200 Day Moving Average: $57.2797 P/E Ratio: 164.10P/E Growth: 1.10Market Cap: $25.654BCurrent Quarter EPS Consensus Estimate: $1.33 EPS Additional Links: View FRX on Google FinanceView FRX on Yahoo FinanceView FRX's Company Profile on ReutersSearch for Forest Laboratories, Inc. on Google Forest Laboratories (NYSE:FRX) Chart for Monday, March, 10, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.